1
|
Sinitca AM, Lyanova AI, Kaplun DI, Hassan H, Krasichkov AS, Sanarova KE, Shilenko LA, Sidorova EE, Akhmetova AA, Vaulina DD, Karpov AA. Microscopy Image Dataset for Deep Learning-Based Quantitative Assessment of Pulmonary Vascular Changes. Sci Data 2024; 11:635. [PMID: 38879569 PMCID: PMC11180164 DOI: 10.1038/s41597-024-03473-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Accepted: 06/04/2024] [Indexed: 06/19/2024] Open
Abstract
Pulmonary hypertension (PH) is a syndrome complex that accompanies a number of diseases of different etiologies, associated with basic mechanisms of structural and functional changes of the pulmonary circulation vessels and revealed pressure increasing in the pulmonary artery. The structural changes in the pulmonary circulation vessels are the main limiting factor determining the prognosis of patients with PH. Thickening and irreversible deposition of collagen in the pulmonary artery branches walls leads to rapid disease progression and a therapy effectiveness decreasing. In this regard, histological examination of the pulmonary circulation vessels is critical both in preclinical studies and clinical practice. However, measurements of quantitative parameters such as the average vessel outer diameter, the vessel walls area, and the hypertrophy index claimed significant time investment and the requirement for specialist training to analyze micrographs. A dataset of pulmonary circulation vessels for pathology assessment using semantic segmentation techniques based on deep-learning is presented in this work. 609 original microphotographs of vessels, numerical data from experts' measurements, and microphotographs with outlines of these measurements for each of the vessels are presented. Furthermore, here we cite an example of a deep learning pipeline using the U-Net semantic segmentation model to extract vascular regions. The presented database will be useful for the development of new software solutions for the analysis of histological micrograph.
Collapse
Affiliation(s)
- Aleksandr M Sinitca
- Centre for Digital Telecommunication Technologies, St. Petersburg Electrotechnical University "LETI", St. Petersburg, 197022, Russia
| | - Asya I Lyanova
- Centre for Digital Telecommunication Technologies, St. Petersburg Electrotechnical University "LETI", St. Petersburg, 197022, Russia
| | - Dmitrii I Kaplun
- Artificial Intelligence Research Institute, China University of Mining and Technology, Xuzhou, 221116, China.
- Department of Automation and Control Processes, St. Petersburg Electrotechnical University "LETI", St. Petersburg, 197022, Russia.
| | - Hassan Hassan
- Department of Automation and Control Processes, St. Petersburg Electrotechnical University "LETI", St. Petersburg, 197022, Russia
| | - Alexander S Krasichkov
- Radio Engineering Systems Department, St. Petersburg Electrotechnical University "LETI", St. Petersburg, 197022, Russia
- Department of Computer Science and Engineering, St. Petersburg Electrotechnical University "LETI", 197022, Saint Petersburg, Russia
| | - Kseniia E Sanarova
- Radio Engineering Systems Department, St. Petersburg Electrotechnical University "LETI", St. Petersburg, 197022, Russia
| | - Leonid A Shilenko
- Institute of Experimental Medicine, Almazov National Medical Research Centre, St. Petersburg, 197341, Russia
| | - Elizaveta E Sidorova
- Institute of Experimental Medicine, Almazov National Medical Research Centre, St. Petersburg, 197341, Russia
| | - Anna A Akhmetova
- Institute of Experimental Medicine, Almazov National Medical Research Centre, St. Petersburg, 197341, Russia
| | - Dariya D Vaulina
- Institute of Experimental Medicine, Almazov National Medical Research Centre, St. Petersburg, 197341, Russia
| | - Andrei A Karpov
- Department of Computer Science and Engineering, St. Petersburg Electrotechnical University "LETI", 197022, Saint Petersburg, Russia
- Institute of Experimental Medicine, Almazov National Medical Research Centre, St. Petersburg, 197341, Russia
| |
Collapse
|
2
|
Karpov AA, Mihailova AM, Cherepanov DE, Chefu SG, Shilenko LA, Vaulina DD, Butskikh MG, Chervaev KA, Sidorova EE, Ivkin DY, Galagudza MM. The Use of Microencapsulated Autologous Thrombi for Modelling Chronic Thromboembolic Pulmonary Hypertension in Rats. Bull Exp Biol Med 2023; 175:616-619. [PMID: 37853268 DOI: 10.1007/s10517-023-05912-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Indexed: 10/20/2023]
Abstract
Here we developed a model of chronic thromboembolic pulmonary hypertension (CTEPH) using repeated intravenous administration of microencapsulated thrombi with a controlled rate of biodegradation. Autologous thrombi encapsulated in alginate microspheres with a diameter of 190±48 μm were intravenously injected to rats 8 times every 4 days. In the comparison group, nonmodified thrombi were injected. After 6 weeks, a significant increase in systolic pressure in the right ventricle, a decrease in exercise tolerance, and an increase in the index of vascular wall hypertrophy were revealed in the group receiving injections of microencapsulated thrombi in comparison with the group receiving nonmodified thrombi and healthy animals. Thus, the developed representative CTEPH model can be used to test promising pharmacological substances.
Collapse
Affiliation(s)
- A A Karpov
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia
- St. Petersburg State Chemical and Pharmaceutical University, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - A M Mihailova
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - D E Cherepanov
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - S G Chefu
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia
- I. P. Pavlov First St. Petersburg State Medical University, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - L A Shilenko
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia
- I. P. Pavlov First St. Petersburg State Medical University, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - D D Vaulina
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia.
| | - M G Butskikh
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia
- I. P. Pavlov First St. Petersburg State Medical University, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - Kh A Chervaev
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia
- I. P. Pavlov First St. Petersburg State Medical University, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - E E Sidorova
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - D Yu Ivkin
- St. Petersburg State Chemical and Pharmaceutical University, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - M M Galagudza
- V. A. Almazov National Medical Research Center, Ministry of Health of the Russian Federation, St. Petersburg, Russia
- I. P. Pavlov First St. Petersburg State Medical University, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| |
Collapse
|
3
|
Karpov AA, Vachrushev NS, Shilenko LA, Smirnov SS, Bunenkov NS, Butskih MG, Chervaev AKA, Vaulina DD, Ivkin DY, Moiseeva OM, Galagudza MM. Sympathetic Denervation and Pharmacological Stimulation of Parasympathetic Nervous System Prevent Pulmonary Vascular Bed Remodeling in Rat Model of Chronic Thromboembolic Pulmonary Hypertension. J Cardiovasc Dev Dis 2023; 10:jcdd10020040. [PMID: 36826536 PMCID: PMC9965116 DOI: 10.3390/jcdd10020040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Revised: 12/28/2022] [Accepted: 01/18/2023] [Indexed: 01/26/2023] Open
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) develops in 1.5-2.0% of patients experiencing pulmonary embolism (PE) and is characterized by stable pulmonary artery obstruction, heart failure, and poor prognosis. Little is known about involvement of autonomic nervous system (ANS) in the mechanisms of CTEPH. This study was aimed at evaluation of the effect of vagal and sympathetic denervation, as well as stimulation of the parasympathetic nervous system, on the outcomes of CTEPH in rats. CTEPH was induced by multiple intravenous injections of alginate microspheres. Sympathetic and vagal denervation was performed using unilateral surgical ablation of the stellate ganglion and vagotomy, respectively. Stimulation of the parasympathetic nervous system was carried out by administering pyridostigmine. The effect of neuromodulatory effects was assessed in terms of hemodynamics, histology, and gene expression. The results demonstrated the key role of ANS in the development of CTEPH. Sympathetic denervation as well as parasympathetic stimulation resulted in attenuated pulmonary vascular remodeling. These salutary changes were associated with altered MMP2 and TIMP1 expression in the lung and decreased FGFb level in the blood. Unilateral vagotomy had no effect on physiological and morphological outcomes of the study. The data obtained contribute to the identification of new therapeutic targets for CTEPH treatment.
Collapse
Affiliation(s)
- Andrei A. Karpov
- Institute of Experimental Medicine, Almazov National Medical Research Centre, 2 Akkuratova Street, 197341 St. Petersburg, Russia
- Department of Experimental Pharmacology, State Federal-Funded Educational Institution of Higher Education, Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Healthcare of the Russian Federation, 14 Professora Popova Street, 197022 St. Petersburg, Russia
| | - Nikita S. Vachrushev
- Institute of Molecular Biology and Genetics, Almazov National Medical Research Centre, 2 Akkuratova Street, 197341 St. Petersburg, Russia
| | - Leonid A. Shilenko
- Institute of Experimental Medicine, Almazov National Medical Research Centre, 2 Akkuratova Street, 197341 St. Petersburg, Russia
| | - Sergey S. Smirnov
- Institute of Experimental Medicine, Almazov National Medical Research Centre, 2 Akkuratova Street, 197341 St. Petersburg, Russia
| | - Nikolay S. Bunenkov
- Institute of Experimental Medicine, Almazov National Medical Research Centre, 2 Akkuratova Street, 197341 St. Petersburg, Russia
- Department of Bone Marrow Transplantation, Raisa Gorbacheva Research Institute of Children Oncology, Hematology and Transplantation of Pavlov First Saint Petersburg State Medical University, 6–8 L’va Tolstogo Street, 197022 St. Petersburg, Russia
| | - Maxim G. Butskih
- Institute of Experimental Medicine, Almazov National Medical Research Centre, 2 Akkuratova Street, 197341 St. Petersburg, Russia
- Department of Pathophysiology with Clinical Pathophysiology Course, Pavlov First Saint Petersburg State Medical University, 6–8 L’va Tolstogo Street, 197022 St. Petersburg, Russia
| | - Al-Khalim A. Chervaev
- Institute of Experimental Medicine, Almazov National Medical Research Centre, 2 Akkuratova Street, 197341 St. Petersburg, Russia
- Department of Pathophysiology with Clinical Pathophysiology Course, Pavlov First Saint Petersburg State Medical University, 6–8 L’va Tolstogo Street, 197022 St. Petersburg, Russia
| | - Dariya D. Vaulina
- Institute of Experimental Medicine, Almazov National Medical Research Centre, 2 Akkuratova Street, 197341 St. Petersburg, Russia
| | - Dmitry Yu. Ivkin
- Department of Experimental Pharmacology, State Federal-Funded Educational Institution of Higher Education, Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Healthcare of the Russian Federation, 14 Professora Popova Street, 197022 St. Petersburg, Russia
| | - Olga M. Moiseeva
- Institute of Heart and Vessels, Almazov National Medical Research Centre, 2 Akkuratova Street, 197022 St. Petersburg, Russia
| | - Michael M. Galagudza
- Institute of Experimental Medicine, Almazov National Medical Research Centre, 2 Akkuratova Street, 197341 St. Petersburg, Russia
- Department of Pathophysiology with Clinical Pathophysiology Course, Pavlov First Saint Petersburg State Medical University, 6–8 L’va Tolstogo Street, 197022 St. Petersburg, Russia
- Correspondence: ; Tel.: +7-921-345-5243
| |
Collapse
|
4
|
Inhibition of JAK1,2 Prevents Fibrotic Remodeling of Pulmonary Vascular Bed and Improves Outcomes in the Rat Model of Chronic Thromboembolic Pulmonary Hypertension. Int J Mol Sci 2022; 23:ijms232415646. [PMID: 36555286 PMCID: PMC9779027 DOI: 10.3390/ijms232415646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 11/15/2022] [Accepted: 12/02/2022] [Indexed: 12/14/2022] Open
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism with poor clinical outcomes. Therapeutic approaches to prevention of fibrotic remodeling of the pulmonary vascular bed in CTEPH are limited. In this work, we tested the hypothesis that Janus kinase 1/2 (JAK1/2) inhibition with ruxolitinib might prevent and attenuate CTEPH in a rat model. CTEPH was induced by repeated embolization of the pulmonary artery with partially biodegradable 180 ± 30 μm alginate microspheres. Two weeks after the last injection of microspheres, ruxolitinib was administered orally at doses of 0.86, 2.58, and 4.28 mg/kg per day for 4 weeks. Prednisolone (1.475 mg/kg, i.m.) was used as a reference drug. Ruxolitinib in all doses as well as prednisolone reduced pulmonary vascular wall hypertrophy. Ruxolitinib at a dose of 2.58 mg/kg and prednisolone reduced vascular wall fibrosis. Prednisolone treatment resulted in decreased right ventricular systolic pressure. Pulmonary vascular resistance was lower in the prednisolone and ruxolitinib (4.28 mg/kg) groups in comparison with the placebo group. The plasma level of brain natriuretic peptide was lower in groups receiving ruxolitinib at doses of 2.58 and 4.28 mg/kg versus placebo. This study demonstrated that JAK1/2 inhibitor ruxolitinib dose-dependently reduced pulmonary vascular remodeling, thereby preventing CTEPH formation in rats.
Collapse
|
5
|
Hard, Soft, and Hard-and-Soft Drug Delivery Carriers Based on CaCO3 and Alginate Biomaterials: Synthesis, Properties, Pharmaceutical Applications. Pharmaceutics 2022; 14:pharmaceutics14050909. [PMID: 35631494 PMCID: PMC9146629 DOI: 10.3390/pharmaceutics14050909] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Revised: 03/26/2022] [Accepted: 04/01/2022] [Indexed: 02/01/2023] Open
Abstract
Because free therapeutic drug molecules often have adverse effects on normal tissues, deliver scanty drug concentrations and exhibit a potentially low efficacy at pathological sites, various drug carriers have been developed for preclinical and clinical trials. Their physicochemical and toxicological properties are the subject of extensive research. Inorganic calcium carbonate particles are promising candidates as drug delivery carriers owning to their hardness, porous internal structure, high surface area, distinctive pH-sensitivity, low degradability, etc, while soft organic alginate hydrogels are also widely used because of their special advantages such as a high hydration, bio-adhesiveness, and non-antigenicity. Here, we review these two distinct substances as well as hybrid structures encompassing both types of carriers. Methods of their synthesis, fundamental properties and mechanisms of formation, and their respective applications are described. Furthermore, we summarize and compare similarities versus differences taking into account unique advantages and disadvantages of these drug delivery carriers. Moreover, rational combination of both carrier types due to their performance complementarity (yin-&yang properties: in general, yin is referred to for definiteness as hard, and yang is broadly taken as soft) is proposed to be used in the so-called hybrid carriers endowing them with even more advanced properties envisioned to be attractive for designing new drug delivery systems.
Collapse
|
6
|
Karpov AA, Vaulina DD, Smirnov SS, Moiseeva OM, Galagudza MM. Rodent models of pulmonary embolism and chronic thromboembolic pulmonary hypertension. Heliyon 2022; 8:e09014. [PMID: 35295664 PMCID: PMC8919224 DOI: 10.1016/j.heliyon.2022.e09014] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 11/06/2021] [Accepted: 02/21/2022] [Indexed: 11/26/2022] Open
Abstract
Pulmonary embolism (PE) is the third most prevalent cardiovascular disease. It is associated with high in-hospital mortality and the development of acute and chronic complications. New approaches aimed at improving the prognosis of patients with PE are largely dependent on reliable animal models. Mice, rats, hamsters, and rabbits, are currently most commonly used for PE modeling because of their ethical acceptability and economic feasibility. This article provides an overview of the main approaches to PE modeling, and the advantages and disadvantages of each method. Special attention is paid to experimental endpoints, including morphological, functional, and molecular endpoints. All approaches to PE modeling can be broadly divided into three main groups: 1) induction of thromboembolism, either by thrombus formation in vivo or by injection of in vitro prepared blood clots; 2) introduction of particles of non-thrombotic origin; and 3) surgical procedures. The choice of a specific model and animal species is determined based on the objectives of the study. Rodent models of chronic thromboembolic pulmonary hypertension (CTEPH), which is the most devastating complication of PE, are also described. CTEPH models are especially challenging because of insufficient knowledge about the pathogenesis and high fibrinolytic activity of rodent plasma. The CTEPH model should demonstrate a persistent increase in pulmonary artery pressure and stable reduction of the vascular bed due to recurrent embolism. Based on the analysis of available evidence, one might conclude that currently, there is no single optimal method for modeling PE and CTEPH.
Collapse
|